Niedernhofer LJ, Garinis GA, Raams A, Lalai AS, Robinson AR, Appeldoorn E, Odijk H, Oostendorp R, Ahmad A, van Leeuwen W, et al
12 mg dose = 1.20 mL (120 units)
The "minimal initial benefit" group (approximately 5-10% of users) reported limited improvements during treatment making discontinuation effects irrelevant, typically explained by inadequate product quality with degraded or low-concentration GHK-Cu, inappropriate application technique reducing absorption, unrealistic expectations exceeding what any topical can achieve, severe underlying pathology requiring medical intervention beyond cosmetic peptides, or individual non-responsiveness to copper peptide treatment for genetic or physiological reasons
Coming Off and Maintenance Semaglutide suppresses appetite but does not reset the biology that resists weight loss
Since the relation of CJC 1295 to cancer has not been established in these studies and cant be established based on whats known in the literature about CJC 1295, if you ever have any concerns, be sure to consult a medical provider before using a substance like CJC 1295
